Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor

British Journal of Pharmacology

Volumn 172, Issue 20, 2015, Pages 4790-4805

  Laprairie, R B ^a   Bagher, A M ^a   Kelly, M E M ^a,b   Denovan Wright, E M ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARRESTIN 2; CANNABIDIOL; CANNABINOID 1 RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHOLIPASE C BETA3; RETINA S ANTIGEN; UNCLASSIFIED DRUG; CANNABINOID RECEPTOR AFFECTING AGENT; PHOSPHOLIPASE C BETA; PLCB3 PROTEIN, HUMAN;

ALLOSTERISM; ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME PHOSPHORYLATION; HEK293 CELL LINE; INTERNALIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TRANSPORT; QUANTITATIVE ANALYSIS; ANIMAL; CELL LINE; HUMAN; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ARRESTINS; CANNABIDIOL; CANNABINOID RECEPTOR MODULATORS; CELL LINE; HEK293 CELLS; HUMANS; MAP KINASE SIGNALING SYSTEM; MICE; PHOSPHOLIPASE C BETA; RECEPTOR, CANNABINOID, CB1;

EID: 84945273580     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13250     Document Type: Article

References (47)

1. Ahn KH, Mahmoud MM, Kendall DA, (2012). Allosteric modulator ORG27569 induces CB1 cannabinoid receptor high affinity agonist binding state, receptor internalization, and Gi protein-independent ERK1/2 kinase activation. J Biol Chem 287: 12070-12082.
2. Ahn KH, Mahmoud MM, Shim JY, Kendall DA, (2013). Distinct roles of β-arrestin 1 and β-arrestin 2 in ORG27569-induced biased signaling and internalization of the cannabinoid receptor 1 (CB1). J Biol Chem 288: 9790-9800.
3. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al, (2013). The Concise Guide to PHARMACOLOGY 2013/14: G Protein-Coupled Receptors. Br J Pharmacol 170: 1459-1581.
4. Anderson RL, Randall MD, Chan SL, (2013). The complex effects of cannabinoids on insulin secretion from rat isolated islets of Langerhans. Eur J Pharmacol 706: 56-62.
5. Bagher AM, Laprairie RB, Kelly ME, Denovan-Wright EM, (2013). Co-expression of the human cannabinoid receptor coding region splice variants (hCB1) affects the function of hCB1 receptor complexes. Eur J Pharmacol 721: 341-354.
6. Baillie GL, Horswill JG, Anavi-Goffer S, Reggio PH, Bolognini D, Abood ME, et al., (2013). CB(1) receptor allosteric modulators display both agonist and signaling pathway specificity. Mol Pharmacol 83: 322-338.
7. Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I, et al., (2001). Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 134: 845-852.
8. Campos AC, Moreira FA, Gomes FV, Del Bel EA, Guimarães FS, (2012). Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philos Trans R Soc Lond B Biol Sci 367: 3364-3378.
9. Canals M, Milligan G, (2008). Constitutive activity of the cannabinoid CB1 receptor regulates the function of co-expressed Mu opioid receptors. J Biol Chem 283: 11424-11434.
10. Cawston EE, Redmond WJ, Breen CM, Grimsey NL, Connor M, Glass M, (2013). Real-time characterization of cannabinoid receptor 1 (CB1) allosteric modulators reveals novel mechanism of action. Br J Pharmacol 170: 893-907.
11. Christopoulos A, Kenakin T, (2002). G protein-coupled receptor allosterism and complexing. Pharmacol Rev 54: 323-374.
12. Fay JF, Farrens DL, (2013). The membrane proximal region of the cannabinoid receptor CB1 N-terminus can allosterically modulate ligand affinity. Biochemistry 52: 8286-8294.
13. Ferreira SG, Teixeira FM, Garção P, Agostinho P, Ledent C, Cortes L, et al., (2012). Presynaptic CB(1) cannabinoid receptors control frontocortical serotonin and glutamate release-species differences. Neurochem Int 61: 219-226.
14. Gamage TF, Ignatowska-Jankowska BM, Wiley JL, Abdelrahman M, Trembleau L, Greig IR, et al., (2014). In-vivo pharmacological evaluation of the CB1-receptor allosteric modulator Org-27569. Behav Pharmacol 25: 182-185.
15. Hayakawa K, Mishima K, Hazekawa M, Sano K, Irie K, Orito K, et al., (2008). Cannabidiol potentiates pharmacological effects of Delta(9)-tetrahydrocannabinol via CB(1) receptor-dependent mechanism. Brain Res 1188: 157-164.
16. Higuchi S, Irie K, Mishima S, Araki M, Ohji M, Shirakawa A, et al., (2010). The cannabinoid 1-receptor silent antagonist O-2050 attenuates preference for high-fat diet and activated astrocytes in mice. J Pharmacol Sci 112: 369-372.
17. Horswill JG, Bali U, Shaaban S, Keily JF, Jeevaratnam P, Babbs AJ, et al., (2007). PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats. Br J Pharmacol 152: 805-814.
18. Hudson BD, Hébert TE, Kelly ME, (2010). Physical and functional interaction between CB1 cannabinoid receptors and beta2-adrenoceptors. Br J Pharmacol 160: 627-642.
19. Hudson BD, Christiansen E, Murdoch H, Jenkins L, Hansen AH, Madsen O, et al., (2014). Complex pharmacology of novel allosteric free fatty acid 3 receptor ligands. Mol Pharmacol 86: 200-210.
20. James JR, Oliveira MI, Carmo AM, Iaboni A, Davis SJ, (2006). A rigorous experimental framework for detecting protein oligomerization using bioluminescence resonance energy transfer. Nat Methods 3: 1001-1006.
21. Kathmann M, Flau K, Redmer A, Tränkle C, Schlicker E, (2006). Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors. Naunyn Schmiedebergs Arch Pharmacol 372: 354-361.
22. Keov P, Sexton PM, Christopoulos A, (2011). Allosteric modulator of G protein-coupled receptors: a pharmacological perspective. Neuropharmacol 60: 24-35.
23. Laprairie RB, Kelly MEM, Denovan-Wright EM, (2013). Cannabinoids increase type 1 cannabinoid receptor expression in a cell culture model of medium spiny projection neurons: implications for Huntington's disease. Neuropharmacol 72: 47-57.
24. Laprairie RB, Bagher AM, Kelly MEM, Dupré DJ, Denovan-Wright EM, (2014a). Type 1 cannabinoid receptor ligands display functional selectivity in a cell culture model of striatal medium spiny projection neurons. J Biol Chem 289: 24845-24862.
25. Laprairie RB, Warford JR, Hutchings S, Robertson GS, Kelly MEM, Denovan-Wright EM, (2014b). The cytokine and endocannabinoid systems are co-regulated by NF-κB p65/RelA in cell culture and transgenic mouse models of Huntington's disease and in striatal tissue from Huntington's disease patients. J Neuroimmunol 267: 61-72.
26. Lee JM, Ivanova EV, Seong IS, Cashorali T, Kohane I, Gusella JF, et al., (2007). Unbiased gene expression analysis implicates the huntingtin polyglutamine tract in extra-mitochondrial energy metabolism. PLoS Genet 3: e135.
27. McPartland JM, Duncan M, Di Marzo V, Pertwee R, (2014). Are cannabidiol and Δ9-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. Br J Pharmacol 172: 737-753.
28. Mechoulam R, Peters M, Murillo-Rodriguez E, Hanus LO, (2007). Cannabidiol-recent advances. Chem Biodivers 4: 1678-1692.
29. Pamplona FA, Ferreira J, Menezes de Lima O,Bento AF, Forner S, et al., (2012). Anti-inflammatory lipoxin A4 is an endogenous allosteric enhancer of CB1 cannabinoid receptor. Proc Natl Acad Sci U S A 109: 21134-21139.
30. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, Davenport AP, McGrath JC, Peters JA, Southan C, Spedding M, Yu W, Harmar AJ,; NC-IUPHAR. (2014) The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucl Acids Res 42 (Database Issue): D1098-1106.
31. Pertwee RG, Ross RA, Craib SJ, Thomas A, (2002). (-)-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens. Eur J Pharmacol 456: 99-106.
32. 1 receptors. Life Sci 76: 1307-1324.
33. Pertwee RG, (2008). Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond. Addict Biol 13: 147-159.
34. Piscitelli F, Ligresti A, La Regina G, Coluccia A, Morera L, Allarà M, et al., (2012). Indole-2-carboxamides as allosteric modulators of the cannabinoid CB1 receptor. J Med Chem 55: 5627-5631.
35. Price MR, Baillie GL, Thomas A, Stevenson LA, Easson M, Goodwin R, et al., (2005). Allosteric modulation of the cannabinoid CB1 receptor. Mol Pharmacol 68: 1484-1495.
36. Ross RA, (2007). Allosterism and cannabinoind CB(1) receptors: the shape of things to come. Trends Pharmacol Sci 28: 567-572.
37. Russo EB, Burnett A, Hall B, Parker KK, (2005). Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res 30: 1037-1043.
38. Ryan D, Drysdale AJ, Pertwee RG, Platt B, (2007). Interactions of cannabidiol with endocannabinoid signalling in hippocampal tissue. Eur J Neurosci 25: 2093-2102.
39. Ryberg E, Larsson N, Sjögren S, Hjorth S, Hermansson NO, Leonova J, et al., (2007). The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152: 1092-1101.
40. Smith NJ, Ward RJ, Stoddart LA, Hudson BD, Kostenis E, Ulven T, et al., (2011). Extracellular loop 2 of the free fatty acid receptor 2 mediates allosterism of phenylacetamide ago-allosteric modulator. Mol Pharmacol 80: 163-173.
41. Sugiura T, Kodaka T, Nakane S, Miyashita T, Kondo S, Suhara Y, et al., (1999). Evidence that the cannabinoid CB1 receptor is a 2-arachidonoylglycerol receptor. Structure-activity relationship of 2-arachidonoylglycerol, ether-linked analogues, and related compounds. J Biol Chem 274: 2794-2801.
42. Thomas A, Baillie GL, Phillips AM, Razdan RK, Ross RA, Pertwee RG, (2007). Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol 150: 613-623.
43. Trettel F, Rigamonti D, Hilditch-Maguire P, Wheeler VC, Sharp AH, Persichetti F, et al., (2000). Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells. Hum Mol Genet 9: 2799-2809.
44. Wang X, Horswill JG, Whalley BJ, Stephens GJ, (2011). Effects of the allosteric antagonist 1-(4-chlorophenyl)-3-[3-(6-pyrrolidin-1-ylpyridin-2-yl)phenyl]urea (PSNCBAM-1) on CB1 receptor modulation in the cerebellum. Mol Pharmacol 79: 758-767.
45. Wiley JL, Breivogel CS, Mahadevan A, Pertwee RG, Cascio MG, Bolognini D, et al., (2011). Structural and pharmacological analysis of O-2050, a putative neutral cannabinoid CB(1) receptor antagonist. Eur J Pharmacol 651: 96-105.
46. Wiley JL, Marusich JA, Zhang Y, Fulp A, Maitra R, Thomas BF, et al., (2012). Structural analogs of pyrazole and sulfonamide cannabinoids: effects on acute food intake in mice. Eur J Pharmacol 695: 62-70.
47. Wootten D, Christopoulos A, Sexton PM, (2013). Emerging paradigms in GPCR allostery: implications for drug discovery. Nat Rev Drug Discov 12: 630-644.